Sign In
Buy ORTX
$16.70
+0 (+0%)
At Close: Mar 15, 2024
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
02:30am, Thursday, 30'th Apr 2026
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom Designation granted under I
Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel
12:15pm, Tuesday, 16'th Dec 2025
Newborn screening is the only practical means of diagnosing MLD prior to the onset of symptoms, which is key to achieving optimal outcomes for children and their families with this rapidly progressive
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
07:00am, Monday, 07'th Jul 2025
Completion of enrollment achieved nearly one year ahead of schedule Primary analysis anticipated two years post-treatment TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Orchard Therape
Orchard Therapeutics Announces Reimbursement Agreement in Spain
03:00am, Friday, 28'th Feb 2025
LONDON, MADRID, and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has recently reached an agreement with the Interministerial Commission for the
First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food and Drug Administration approval last year
Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS Featured data sh
Orchard Therapeutics Announces Multiple Data Presentations and Publications
11:30am, Wednesday, 23'rd Oct 2024
Ten presentations at ESGCT 2024 detail the therapeutic potential and applicability of the company's platform in rare neurometabolic diseases and beyond
ISTANBUL and LONDON, and BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients a
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024
07:00am, Wednesday, 28'th Aug 2024
LONDON and BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the glob
A nomination to add MLD to the U.S. Recommended Uniform Screening Panel has been submitted by a multi-disciplinary expert working group
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
01:18am, Monday, 20'th May 2024
Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and bluebird bio (NASDAQ:BLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compar
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
07:00am, Tuesday, 07'th May 2024
Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond Eight presentations showcase the broad applicability of HSC gene therapy to
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
07:00am, Friday, 03'rd May 2024
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around th
Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) One-time treatment with
